The backbone of progress--preclinical studies and innovations with zoledronic acid.

@article{Green2011TheBO,
  title={The backbone of progress--preclinical studies and innovations with zoledronic acid.},
  author={Jonathan R B Green and Andreas G{\"u}nther},
  journal={Critical reviews in oncology/hematology},
  year={2011},
  volume={77 Suppl 1},
  pages={S3-S12}
}
Bisphosphonates (BPs) are antiresorptive agents that block pathologic bone resorption by inhibiting osteoclast function and later inducing osteoclast apoptosis. These agents localize to bone and break the vicious cycle of bone resorption that results from cross-stimulation between cancer cells and the bone remodeling cells, thereby reducing cancer-induced osteolysis and the tumor burden in bone. Thus nitrogen-containing BPs (N-BPs) have well established clinical benefits in the treatment of… CONTINUE READING
17 Citations
88 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 88 references

Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

  • Fleisch H. Bisphosphonates
  • Drugs 1991;42:919−44
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…